PK/PD Study Services for Influenza
Understanding the relationship between drug exposure and therapeutic response is fundamental to optimizing influenza treatment. Our specialized pharmacokinetic/pharmacodynamic (PK/PD) studies are designed to elucidate how antiviral agents and immunomodulators behave within the body and how these dynamics translate to efficacy against influenza infection. By precisely characterizing the interplay between drug concentration, distribution, and therapeutic outcome, our PK/PD services provide critical data to inform effective dosing strategies and accelerate the development of novel influenza therapeutics.
We offer a comprehensive suite of administration routes to support diverse influenza research objectives, including oral, intravenous, intraperitoneal, and intranasal delivery. These flexible options enable the investigation of various drug delivery strategies, allowing for the assessment of systemic versus localized effects, evaluation of bioavailability, and modeling of clinically relevant administration practices. Our capabilities ensure that the most appropriate route can be selected to answer specific research questions and mirror intended clinical use.
Our PK/PD services encompass extensive compartment analysis, with the ability to quantitatively measure drug and biomarker concentrations in a wide range of biological matrices. We routinely analyze blood, plasma, serum, bronchoalveolar lavage fluid, lung, brain, liver, spleen, kidney, and intestine. This enables detailed mapping of drug distribution and target engagement in both systemic circulation and tissues directly impacted by influenza pathogenesis, such as the respiratory tract and associated organs.
We employ a robust portfolio of advanced analytical techniques to ensure precise and sensitive quantification of drugs and biomarkers. Our methods include high-performance liquid chromatography (HPLC), HPLC with fluorescence detection (HPLC-F), HPLC with UV detection (HPLC-UV), HPLC with refractive index detection (HPLC-R), ultra-performance liquid chromatography-mass spectrometry (UPLC-MS), liquid chromatography-mass spectrometry (LC-MS), mass spectrometry, and enzyme-linked immunosorbent assay (ELISA). These technologies support comprehensive validation, facilitate the detection of low-abundance analytes, and enable in-depth PK/PD modeling for influenza therapeutics.
Our research platform supports a wide array of preclinical animal models, including rats, mice, rabbits, dogs, and monkeys. This diversity allows for the selection of species most relevant to specific influenza research goals, whether for initial proof-of-concept studies, translational modeling, or interspecies scaling. Each model offers unique physiological and immunological characteristics, providing valuable insights into drug behavior, safety, and efficacy across different biological systems.
Our integrated PK/PD studies deliver actionable insights critical to influenza drug development, including comprehensive characterization of absorption, distribution, metabolism, and excretion (ADME) properties; establishment of concentration-effect relationships; optimization of dosing regimens; and interspecies scaling for translational research. These data underpin rational decision-making throughout the therapeutic development pipeline.
With deep expertise in influenza research and a commitment to scientific excellence, we are your trusted partner for comprehensive PK/PD studies. Our end-to-end service capabilities, advanced technologies, and experienced team ensure robust, translatable results to accelerate your influenza therapeutic programs. We invite you to collaborate with us to advance the next generation of influenza treatments.
Make Order
Experimental Scheme
Implementation
Conclusion
